-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

Benzinga·10/19/2026 16:33:14
语音播报
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.